/
Metabolic & Endocrine
Hypercholesterolemia
23
Pipeline Programs↗
45
Active Trials↗
52
Companies Involved↗
Hypercholesterolemia is an emerging landscape with 23 programs across 52 companies. The most active players are Merck & Co., LIB Therapeutics LLC, Beijing Suncadia Pharmaceuticals Co., Ltd. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 14
Phase 39
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
18 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 96% of 23 pipeline programs.
Analysis
Trial Status
300
clinical trials
Completed209 · 70%
Terminated24 · 8%
Recruiting18 · 6%
Not yet recruiting15 · 5%
Unknown status14 · 5%
Active, not recruiting11 · 4%
Other9 · 3%
Clinical Trials
Trial Activity
300 trials
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH): A Real World, Prospective and Retrospective, Observational Study
Recruiting·FFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)·N/A·NCT07447648·52 enrolled
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 1·NCT06461702·13 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)